U.S. COMPANY FILING
ABBOTT LABORATORIES — Form 10-K filed 2026-02-20
Filing text preview
Abbott's 2025 10-K shows sales growth driven by Medical Devices and Established Pharmaceuticals, with operating margin up to 18.2%. The company plans to acquire Exact Sciences with ~$20B borrowings, increasing debt. Dividends raised to $2.40/share, and share repurchases continued. Risks include regulatory, manufacturing, and cybersecurity.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record